iptacopan
Phase 3Recruiting 0 views this week 0 watching⚡ Active
Interest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Immunoglobulin A Nephropathy (IgAN)
Conditions
Primary Immunoglobulin A Nephropathy (IgAN)
Trial Timeline
Nov 27, 2025 → Jun 30, 2030
NCT ID
NCT06994845About iptacopan
iptacopan is a phase 3 stage product being developed by Novartis for Primary Immunoglobulin A Nephropathy (IgAN). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06994845. Target conditions include Primary Immunoglobulin A Nephropathy (IgAN).
What happened to similar drugs?
20 of 20 similar drugs in Primary Immunoglobulin A Nephropathy (IgAN) were approved
Approved (20) Terminated (6) Active (0)
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (11)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05222412 | Pre-clinical | Active |
| NCT06994845 | Phase 3 | Recruiting |
| NCT06903234 | Pre-clinical | Active |
| NCT06797518 | Phase 2 | Recruiting |
| NCT06517758 | Phase 3 | Recruiting |
| NCT05935215 | Phase 3 | Recruiting |
| NCT05630001 | Phase 3 | Completed |
| NCT04889430 | Phase 3 | Active |
| NCT05086744 | Phase 2 | Terminated |
| NCT04747613 | Phase 3 | Active |
| NCT03439839 | Phase 2 | Completed |
Competing Products
20 competing products in Primary Immunoglobulin A Nephropathy (IgAN)